Prime Medicine (PRME) Income from Non-Controlling Interests (2021 - 2026)
Prime Medicine (PRME) posted Income from Non-Controlling Interests of -$83000.0 for Q1 2026, down 269.39% on a QoQ basis from $49000.0 in Q4 2025, and down 418.75% year-over-year from $26039.2 in Q1 2025.
Prime Medicine (PRME) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Prime Medicine's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$83000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 418.75% year-over-year to -$83000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14000.0 (down 82.5% YoY) and the FY2025 annual result came in at $81000.0, up 406.25% from the prior year.
- Income from Non-Controlling Interests was -$83000.0 for Q1 2026 at Prime Medicine, down from $49000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $179000.0 in Q1 2023 and bottomed at -$304000.0 in Q3 2022.
- A 5-year average of $1529.4 and a median of $5000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests tumbled 1316.0% — and 2023, when it jumped 3680.0%.
- Prime Medicine's Income from Non-Controlling Interests stood at $70000.0 in 2022, then jumped by 91.43% to $134000.0 in 2023, then plunged by 114.93% to -$20000.0 in 2024, then jumped by 345.0% to $49000.0 in 2025, then sank by 269.39% to -$83000.0 in 2026.
- Business Quant data shows PRME's Income from Non-Controlling Interests at -$83000.0 in Q1 2026, $49000.0 in Q4 2025, and $43000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Prime Medicine | 549.88 Mn | 549.88 Mn | - | -83,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | -16,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | -80,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | -63,000.00 |
| Mar 31, 2023 | 179,000.00 |
| Dec 31, 2022 | 70,000.00 |
| Sep 30, 2022 | -304,000.00 |
| Jun 30, 2022 | -118,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | -18,000.00 |
| Sep 30, 2021 | 25,000.00 |